RxDoctor Payments Data

Jessica Sparks, APRN

Acute Care · Huntington, WVNPI 1306302468

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 47.5% of the total. Among acute care clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,596in general payments, 2019–2025

Across 164 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Pfizer$301
  • Novartis$259
  • Johnson & Johnson$140
  • Boston Scientific$88
  • Indivior Inc.$88
  • plus $485 from 16 others

What the payments were for

  • Food & beverage$2,596100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,596 in reported general payments places this provider in the 90th percentile of 51 acute care providers in West Virginia.

See all acute care providers in West Virginia

Medicare billing

Part B allowed, 2024
$30,207
Medicare patients
289
Services billed
610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban330$379,250
XareltoRivaroxaban117$131,913
MultaqDronedarone Hcl95$108,017
Dofetilide98$31,980
EntrestoSacubitril/Valsartan18$24,818
Flecainide Acetate227$6,555
Metoprolol Succinate383$5,922
SotalolSotalol Hcl168$2,505
Diltiazem 24hr Er (Cd)Diltiazem Hcl70$1,954
Amiodarone Hcl74$1,489
Eplerenone14$1,333
Mexiletine Hcl18$1,288
Propafenone Hcl24$716
Carvedilol69$560
Diltiazem Hcl19$550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$301$379,250330 claims
Johnson & JohnsonXarelto$140$131,913117 claims
Sanofi-aventis U.S. LLCMultaq$20$108,01795 claims
NovartisEntresto$259$24,81818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 51 acute care providers in West Virginia.

Other acute care in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →